Significance of Meeting the Primary Endpoint in Phase 3

Merck & Co. (MRK) and Sichuan Kelun-Biotech Biopharmaceutical (HKG: 6990), a Chinese company, are jointly developing sacituzumab tirumotecan (sac-TMT), a Trop2-targeted antibody-drug conjugate (ADC), which has achieved its primary endpoint in a Phase 3 trial (OptiTROP-Lung06). This Phase 3 trial represents a significant milestone in the first-line treatment of non-small cell lung cancer (NSCLC), with the potential to replace existing chemotherapy regimens. The success of this clinical trial reinforces Merck's strategic initiative to replace the current standard of care, which involves the combination of immune checkpoint inhibitors and chemotherapy, with an ADC-based combination therapy.

Innovative Treatment Option for Difficult-to-Treat Patient Population

The key patient population in this trial consisted of patients with metastatic non-squamous NSCLC who lack driver gene mutations and have negative PD-L1 expression (less than 1%). These patients typically have poor prognoses when treated with immune checkpoint inhibitors alone, necessitating the use of highly toxic chemotherapy, making this a significant therapeutic bottleneck. The combination therapy of sac-TMT and pembrolizumab (Keytruda) demonstrated statistically significant improvement in progression-free survival (PFS) compared to the control group, which received pembrolizumab and pemetrexed plus platinum-based chemotherapy, significantly improving patient survival.

Merck's Strategy to Prepare for Keytruda Patent Expiration

The NSCLC treatment market is a massive oncology market, estimated at approximately $24 billion to $27.7 billion (USD) in 2026. With the upcoming expiration of the U.S. patent for Keytruda, Merck's flagship cancer drug, in 2028, the company faces a critical commercial challenge to diversify its portfolio. Therefore, the successful proof-of-concept of sac-TMT is considered a significant achievement, demonstrating its potential to become Merck's next-generation growth driver and a cornerstone of its oncology franchise.

Fierce Competition in the Trop2 ADC Market

The Trop2 ADC market is currently dominated by datopotamab deruxtecan (Dato-DXd) from AstraZeneca and Daiichi Sankyo, and trodelvy from Gilead, all vying for market share. Despite being a later entrant, sac-TMT has demonstrated differentiated clinical efficacy by achieving the first successful Phase 3 trial in the challenging first-line treatment setting. This success reaffirms the value of ADC technology, which delivers cytotoxic agents directly to cancer cells, reducing systemic side effects.

Global Clinical Expansion and Smart Financing

Although this trial was conducted only on patients in China and does not immediately translate into regulatory approval in the United States or Europe, it serves as a strong catalyst for the success of Merck's 17 ongoing global Phase 3 trials (TroFuse series), which are aimed at expanding its global reach. To reduce development costs, Merck also implemented a smart risk-sharing strategy by securing $700 million in co-development funding from Blackstone Life Sciences last year. The detailed hazard ratio (HR) data for overall survival (OS), which will be presented at future conferences, will be the next key data point to watch.